In advanced stage prostate cancer, the first site of involvement is often bones.; More than 90 percent of patients have bone involvement.;In the majority of these patients, the only site of involvement is the bones. Apart from bone, internal organ involvement is most common in the liver, lung, brain and adrenal glands. The disease tends to progress more rapidly in patients with internal organ involvement. The first step in the treatment of newly diagnosed advanced prostate cancer is to suppress the testosterone hormone. For this purpose, the testicles are removed by surgery.
With treatments aimed at suppressing hormones, the disease can last for 3-4 years. can be brought under control.; However, over time, hormone suppressive treatments are not sufficient and the disease begins to progress despite these treatments. Until recent years, subsequent treatments were pain-relieving approaches aimed at reducing the patient's complaints. There was no treatment approach that could extend the patient's life expectancy after resistance to hormone treatments developed.; Prostate cancer was also considered resistant to chemotherapy drugs.;;
Until now, chemotherapy applications in prostate cancers were always reserved for advanced stages after the development of resistance to hormone treatments. In a study announced this week at the Oncology Congress in Chicago, it was announced that chemotherapy started early in advanced prostate cancers contributes much more to the survival of patients than chemotherapy started late. In this study, in which 790 patients participated, it was shown that chemotherapy administered together with hormone suppressing drugs at the beginning of the treatment provided a survival advantage of up to one and a half years in patients. This study proved that it would be more appropriate to use chemotherapy at the beginning of the disease rather than saving it for the end, especially in patients with internal organ involvement that is expected to worsen rapidly. .;
The use of radioactive isotopes in the treatment of bone disease was only used in patients with bone involvement; It was aimed at relieving pain. Samarium treatment significantly reduced bone pain.; Samarium is still used for this purpose.;
It is radioactive for both bone metastases in prostate cancer patients who develop resistance to hormone suppressive treatments in advanced stages; with isotope rla; At the beginning of the treatments, as well as at the beginning of the treatments; The demonstration that chemotherapy administered afterwards prolongs the life of patients has opened new horizons and changed treatment standards for patients with advanced prostate cancer.
Read: 0
